The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Zavalishina L.E.

Russian Medical Academy of Continuous Professional Education, Moscow, Russia

Vtorushin S.V.

Siberian State Medical University, Tomsk, Russia;
Cancer Research Institute, Tomsk National Research Medical Center, Tomsk, Russia

Raskin G.A.

Medical Institute named after Berezin Sergey, St. Petersburg, Russia;
St. Petersburg State University, St. Petersburg, Russia

Petrov S.V.

Kazan Medical University, Kazan, Russia

Andreeva Yu.Yu.

Russian Medical Academy of Continuous Professional Education, Moscow, Russia

Barinov A.A.

Moscow City Oncology Hospital No. 62, Moscow, Russia

Vinogradov I.Yu.

Regional Clinical Oncology Dispensary, Ryazan, Russia

Demidova, I.A.

Moscow City Oncology Hospital No. 62, Moscow, Russia

Kuznetsova O.A.

Russian Medical Academy of Continuous Professional Education, Moscow, Russia

Olyushina E.M.

Russian Medical Academy of Continuous Professional Education, Moscow, Russia

Savelov N.A.

Moscow City Oncology Hospital No. 62, Moscow, Russia

Akhmedova Iu.Kh.

Russian Medical Academy of Continuous Professional Education, Moscow, Russia

Frank G.A.

Russian Medical Academy of Continuous Professional Education, Moscow, Russia

Quality control of immunohistochemical studies in Russia in 2025: achievement and prospects

Authors:

Zavalishina L.E., Vtorushin S.V., Raskin G.A., Petrov S.V., Andreeva Yu.Yu., Barinov A.A., Vinogradov I.Yu., Demidova, I.A., Kuznetsova O.A., Olyushina E.M., Savelov N.A., Akhmedova Iu.Kh., Frank G.A.

More about the authors

Read: 345 times


To cite this article:

Zavalishina LE, Vtorushin SV, Raskin GA, et al. Quality control of immunohistochemical studies in Russia in 2025: achievement and prospects. Russian Journal of Archive of Pathology. 2026;88(2):59‑66. (In Russ.)
https://doi.org/10.17116/patol20268802159

Recommended articles:
Soli­tary fibrous tumor of the kidney. Russian Journal of Archive of Pathology. 2025;(3):77-81
Quality control of HLA-typing in labo­ratories in Russia. Labo­ratory Service. 2025;(2):24-28
Orga­nization of the HLA-typing labo­ratories. Labo­ratory Service. 2025;(3):26-32

References:

  1. Zavalishina LE, Artemyeva AS, Vtorushin SV, et al. Analysis of the work of the Immunohistochemical Quality Control Center of the Russian Medical Academy of Continuous Professional Education of the Ministry of Health of Russia in 2023. Russian Journal of Archive of Pathology. 2024;86(3):38-45. (In Russ.) https://doi.org/10.17116/patol20248603138
  2. Zavalishina LE, Andreeva YuYu, Barinov AA, et al. Quality control of immunohistochemical studies: compulsory duty or urgent need? Russian Journal of Archive of Pathology. 2025;87(2):43-52. (In Russ.) https://doi.org/10.17116/patol20258702143
  3. The Ministry of Health of Russian Federation Clinical recommendations. Breast cancer. 2021 (In Russ.) https://cr.minzdrav.gov.ru/recomend/379_4
  4. Wolff AC, Somerfield MR, Dowsett M, et al. Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology-College of American Pathologists Guideline Update. Arch Pathol Lab Med. Jun 7 2023. https://doi.org/10.5858/arpa.2023-0950-SA
  5. Zavalishina LE, Gorban NA, Vtorushin SV et al. Rukovodstvo po testirovaniyu HER2-statusa. Zlokachestvennye opukholi, 2024. 36p. (In Russ.) https://doi.org/10.18027/2224-5057-2024-10e-36
  6. Meric-Bernstam F, Makker V, Oaknin A, et al. Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial. J Clin Oncol. Jan 1 2024;42(1):47-58.  https://doi.org/10.1200/jco.23.02005

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.